NASDAQ:EDIT - Editas Medicine Stock Price, Price Target & More

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

Editas Medicine Inc (NASDAQ:EDIT) issued its quarterly earnings results on Thursday, May, 3rd. The company reported ($0.67) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.82) by $0.15. The company earned $3.90 million during the quarter, compared to the consensus estimate of $4.04 million. Editas Medicine had a negative net margin of 707.98% and a negative return on equity of 58.73%. Editas Medicine's revenue was up 473.5% on a year-over-year basis. During the same period in the prior year, the company earned ($0.85) EPS. View Editas Medicine's Earnings History.

Editas Medicine is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Editas Medicine.

10 equities research analysts have issued 1-year price objectives for Editas Medicine's shares. Their predictions range from $27.00 to $67.00. On average, they expect Editas Medicine's stock price to reach $47.1667 in the next twelve months. View Analyst Ratings for Editas Medicine.

Some companies that are related to Editas Medicine include BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), argenx (ARGX), Spark Therapeutics (ONCE), Crispr Therapeutics (CRSP), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Atara Biotherapeutics (ATRA), Repligen (RGEN), Regenxbio (RGNX), Momenta Pharmaceuticals (MNTA), Denali Therapeutics (DNLI), Acceleron Pharma (XLRN) and Sangamo Therapeutics (SGMO).

(EDIT) raised $100 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

Media coverage about EDIT stock has been trending somewhat positive recently, according to Accern Sentiment. Accern ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Editas Medicine earned a media sentiment score of 0.24 on Accern's scale. They also assigned media headlines about the company an impact score of 46.50 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Editas Medicine's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.07%), Global Thematic Partners LLC (1.00%), Northern Trust Corp (0.89%), Millennium Management LLC (0.66%), Federated Investors Inc. PA (0.54%) and UBS Group AG (0.45%). Company insiders that own Editas Medicine stock include Alexandra Glucksmann, Andrew A F Hack, Boris Nikolic, Charles Albright, Gerald Frank Cox, Jessica Hopfield, Katrine Bosley, Kevin Bitterman, Kevin P Starr and Polaris Venture Management Co. View Institutional Ownership Trends for Editas Medicine.

EDIT stock was sold by a variety of institutional investors in the last quarter, including Global Thematic Partners LLC, Millennium Management LLC, American Century Companies Inc., Commonwealth Equity Services LLC, Artal Group S.A., Guggenheim Capital LLC, Cim Investment Mangement Inc. and M&T Bank Corp. Company insiders that have sold Editas Medicine company stock in the last year include Andrew A F Hack, Charles Albright and Katrine Bosley. View Insider Buying and Selling for Editas Medicine.

EDIT stock was acquired by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, BlackRock Inc., Elmwood Wealth Management Inc., UBS Group AG, Trexquant Investment LP, Northern Trust Corp, Schwab Charles Investment Management Inc. and Great West Life Assurance Co. Can. Company insiders that have bought Editas Medicine stock in the last two years include Boris Nikolic, Gerald Frank Cox and Jessica Hopfield. View Insider Buying and Selling for Editas Medicine.

Shares of EDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of EDIT stock can currently be purchased for approximately $39.39.

Editas Medicine has a market capitalization of $1.77 billion and generates $13.73 million in revenue each year. The company earns $-120,320,000.00 in net income (profit) each year or ($2.98) on an earnings per share basis. Editas Medicine employs 112 workers across the globe.

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The company can be reached via phone at 617-401-9000 or via email at [email protected]